Loading...
Market
What will be Mankind Pharma's revenue growth for fiscal year ending March 31, 2025?
3
Resolution / Starting Odds
Less than 5% growth • 25%
5% to 10% growth • 25%
10% to 20% growth • 25%
More than 20% growth • 25%
Financial statements from Mankind Pharma, financial news outlets, or stock exchange records
Story
Mankind Pharma Secures CCI Approval for ₹13,360 Crore Bharat Serums Acquisition
Oct 2, 2024, 02:01 AM
Mankind Pharma has received approval from the Competition Commission of India (CCI) for its acquisition of Bharat Serums and Vaccines Limited. The acquisition deal is valued at ₹13,360 crore (approximately $1.6 billion), though some reports indicate a value of Rs 13,630 crore. This transaction involves Mankind Pharma acquiring 100% shareholding of Bharat Serums and Vaccines Limited. Mankind Pharma is India's fourth-largest drug maker.
View original story
Similar markets
Decrease • 25%
0-5% increase • 25%
5-10% increase • 25%
More than 10% increase • 25%
Below 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
Above 15% • 25%
Less than 3% • 25%
3% to 5% • 25%
5% to 7% • 25%
More than 7% • 25%
Negative growth • 25%
0-5% growth • 25%
5-10% growth • 25%
Over 10% growth • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Below $147 billion • 25%
$147 billion to $151 billion • 25%
Above $151 billion • 25%
Not disclosed • 25%
Less than 5% growth • 25%
5% to 10% growth • 25%
10% to 20% growth • 25%
More than 20% growth • 25%
Revenue increases by more than 20% • 25%
Revenue increases by 10-20% • 25%
Revenue increases by less than 10% • 25%
Revenue decreases • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%